Skip to main content

Internal Medicine Alert

RSS  

Articles

  • And Then What Happens?

    You are consulted on the electrocardiogram (ECG) in the figure — but without the benefit of any clinical information. This tracing was assessed as showing AFib (atrial fibrillation) with a controlled ventricular response. Do you agree?

  • Vimseltinib (Romvimza) Capsules for TGCT

    The U.S. Food and Drug Administration has approved vimseltinib for the treatment of tenosynovial giant cell tumor for which surgical resection is not desirable.

  • Paxlovid: Is It Still Worth the Cost?

    Paxlovid is one of the most effective antivirals developed during the COVID-19 years, demonstrating significant reductions in hospitalization and death in higher-risk persons, as well as the time to viral elimination. However, it does not shorten the duration of symptoms, and there is little evidence that Paxlovid reduces the risk of developing long COVID symptoms.

  • The Effect of High-Dose Vitamin D on Clinically Isolated Syndrome and MS

    This study by Thouvenot et al evaluated the effectiveness of high-dose vitamin D treatment on clinically isolated syndrome and early multiple sclerosis as monotherapy and reported a reduced incidence of new disease activity compared to the control group.

  • Antibiotics for Asymptomatic Bacteriuria: Using Urinalysis to Improve Stewardship

    A cohort study found that in patients receiving antibiotics for a urinary tract infection, a urinalysis with pyuria and/or nitrituria identified 40% more cases of unnecessary antibiotic use compared to asymptomatic bacteriuria.

  • Can Anti-Amyloid Antibody Treatment Delay the Clinical Onset of Alzheimer’s Disease?

    In this open-label extension of the dominantly inherited Alzheimer’s disease gantenerumab trial (DIAN-TU), long-term continuous amyloid clearance over eight or more years in asymptomatic carriers of autosomal dominant Alzheimer’s mutations showed potential to delay symptom onset and slow progression. Shorter duration or partial clearance did not yield measurable clinical benefit, suggesting that only sustained, near-complete amyloid removal may have disease-modifying effects.

  • Manual Maneuvers for the Treatment of Benign Positional Vertigo

    Benign positional vertigo is a challenge to treat. This clinical trial from investigators in South Korea demonstrated modest efficacy in resolving posterior canal-related vertigo with a head-shaking maneuver that is easily performed in an office setting.

  • Gepotidacin Tablets (Blujepa)

    The U.S. Food and Drug Administration has approved gepotidacin, a first-in-class antibacterial medication for the treatment of uncomplicated urinary tract infections.

  • Use of Coronary Calcium Score in Familial Coronary Artery Disease

    A randomized trial of computed tomography (CT) coronary artery calcium score augmented management vs. usual care of primary prevention patients at moderate risk of a coronary event and with a family history of premature coronary events has shown that, after three years of follow-up, the calcium score group had lower low-density lipoprotein cholesterol levels and smaller total plaque volumes by CT angiography.

  • Systolic Blood Pressure Targets in Octogenarians

    An analysis of a U.S. national database of patients 80 years of age or older taking antihypertensive agents was analyzed to determine the optimal systolic blood pressure associated with the lowest cardiovascular mortality and found that the ideal target was < 130 mmHg.